Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Common Equity: 2010-2025

Historic Common Equity for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to $503.4 million.

  • Arrowhead Pharmaceuticals' Common Equity rose 163.48% to $503.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $503.4 million, marking a year-over-year increase of 163.48%. This contributed to the annual value of $503.4 million for FY2025, which is 163.48% up from last year.
  • According to the latest figures from Q3 2025, Arrowhead Pharmaceuticals' Common Equity is $503.4 million, which was down 3.62% from $522.3 million recorded in Q2 2025.
  • Arrowhead Pharmaceuticals' Common Equity's 5-year high stood at $684.2 million during Q1 2025, with a 5-year trough of $56.1 million in Q4 2024.
  • In the last 3 years, Arrowhead Pharmaceuticals' Common Equity had a median value of $382.0 million in 2023 and averaged $372.7 million.
  • In the last 5 years, Arrowhead Pharmaceuticals' Common Equity plummeted by 67.72% in 2024 and then skyrocketed by 163.48% in 2025.
  • Quarterly analysis of 5 years shows Arrowhead Pharmaceuticals' Common Equity stood at $372.6 million in 2021, then grew by 6.39% to $396.4 million in 2022, then tumbled by 56.17% to $173.7 million in 2023, then plummeted by 67.72% to $56.1 million in 2024, then skyrocketed by 163.48% to $503.4 million in 2025.
  • Its last three reported values are $503.4 million in Q3 2025, $522.3 million for Q2 2025, and $684.2 million during Q1 2025.